

IL-1 β (pg/ml)
5000
4000
3000
2000
1000
0
None
LPS
LPS+Alum
LPS+OxPAPC
LPS+PGPC
Alum
OxPAPC
PGPC
TNFα (pg/ml)
6000
4000
2000
0
None
LPS
LPS+Alum
LPS+OxPAPC
LPS+PGPC
Alum
OxPAPC

FIG. 1A



%LDH
80
60
40
20
0
**
None
LPS
LPS+Alum
LPS+OxPAPC
LPS+PGPC
Alum
OxPAPC
PGPC

FIG. 1B



CD40 (MFI)
(gated on live cells)
4×10^4
3×10^4
2×10^4
1×10^4
0
**
**
*
None
LPS
LPS+OxPAPC
LPS+PGPC
LPS+Alum
OxPAPC
PGPC
Alum

FIG. 1C



IL-12p70 (pg/ml)
800
600
400
200
0
**
**
**
**
None
LPS
LPS+OxPAPC
LPS+PGPC
LPS+Alum
OxPAPC
PGPC
Alum

FIG. 1D



Frequency of OVA-FITC+ BMDCs
100
80
60
40
20
0
***
None
LPS
LPS+OxPAPC
LPS+PGPC
LPS+Alum
OxPAPC
PGPC
Alum
Frequency of SIINFEKL+ BMDCs
**
ns
***

FIG. 1E



OT-II T cells
OT-I T cells
IFNγ (pg/ml)
IL-13 (pg/ml)
IL-10 (pg/ml)
IL-2 (pg/ml)
TNF-α (pg/ml)
ns
n.d.n.d
OVA
SIINFEKL
LPS
OxPAPC
PGPC
Alum
BMDCs
GMCSF

FIG. 1F



OT-II T cells
IFNγ+TNFα+/IL10+IL4+ (TH1/TH2 ratio)
200
150
100
50
0
*
*
None
LPS
LPS+PGPC
LPS+Alum
OT-II+BMDC +OVA
OT-I T cells
Frequency of IFNγ+CD8+ T cells
10
8
6
4
2
0
*
None
LPS
LPS+PGPC
LPS+Alum
OT-I+BMDC +OVA

FIG. 1G



dLN CD8+T cells
None
OVAp
IFN-γ (pg/ml)
25000
15000
10000
5000
0
Immunization
None
LPS
LPS+OXPAPC
LPS+PGPPC
+OVA in IFA
+OVA in Alum
dLN CD4+T cells
None
OVA
IFN-γ (pg/ml)
15000
10000
5000
0
Immunization
None
LPS
LPS+OXPAPC
LPS+PGPPC
+OVA in IFA
+OVA in Alum
dLN CD4+T cells
None
OVA
IL-10 (pg/ml)
2000
1500
1000
500
0
Immunization
None
LPS
LPS+OXPAPC
LPS+PGPPC
+OVA in IFA
+OVA in Alum
dLN CD4+T cells
None
OVA
IL-13 (pg/ml)
400
300
200
100
0
Immunization
None
LPS
LPS+OXPAPC
LPS+PGPPC
+OVA in IFA
+OVA in Alum

FIG. 1H



dLN T cells
CD44loCD62Llo (Teff)
% of Teff CD4+ T cells
CD44loCD62Llo (Teff)
% of Teff CD8+ T cells
1 None
2 LPS
3 LPS+OxPAPC
4 LPS+PGPC
5 PGPC
+OVA
CD44hiCD62Llo (TEM)
% of TEM CD4+ T cells
CD44hiCD62Llo (TEM)
% of TEM CD8+ T cells
CD44hiCD62Lhi (TCM)
% of TCM CD4+ T cells
CD44hiCD62Lhi (TCM)
% of TCM CD8+ T cells
7d
40d
1 2 3 4 5 1 2 3 4 5

FIG. 2A



Gated on Live CD8+T cells
% of CD107a+
100
75
50
25
0
****
**
PMA/IONO
Target cells
1 2 3 4 5
1 2 3 4 5
1 None
2 LPS
3 LPS+OxPAPC
4 LPS+PGPC
5 PGPC
+OVA

FIG. 2B



1 OVA
2 OVA+LPS
3 OVA+LPS+OxPAPC
4 OVA+LPS+PGPC
4 OVA+LPS+PGPC (NLRP3-/-)
5 OVA+LPS+Alum
6 LPS+PGPC (NO OVA)
in vivo immunization
% of SIINFEKL+ IFNγ+ T cells
OVA 50µg/ml
OVA 500µg/ml
BMDC+ CD8+T cells
(1:10)
% of AAHAEINEA+ IFNγ+ T cells
OVA 50µg/ml
OVA 500µg/ml
BMDC+ CD4+T cells
(1:10)

FIG. 2C



Inguinal adipose tissue T cells
% of CD44+ memory T cells
80
60
40
20
0
1 2 3 4 5 6
**
**
**
1 OVA
2 OVA+LPS
3 OVA+LPS+OxPAPC
4 OVA+LPS+PGPC (WT mice)
OVA+LPS+PGPC (NLRP3-/- mice)
5 OVA+LPS+Alum
6 OVA+PGPC

FIG. 2D



Unimmunized
None
LPS
LPS+OxPAPC
LPS+PGPC
+ B16OVA WTL
Tumor Volume (mm²)
500
400
300
200
100
0
B16OVA
Rechallenge
4
14
24
34
44
150
164
174
184
194
300
Days post tumor Challenge
B16OVA
Rechallenge
100
75
50
25
0
% of survival
Unimmunized
None
LPS
LPS+OxPAPC
LPS+PGPC
+ B16OVA WTL
0
30
60
90
120
150
180
210
240
270
300
Days post tumor challenge

FIG. 3A



TILs
% of CD45+ CD3+ Live cells
60
40
20
0
CD4+
CD8+
CD3+ TILs
IFNγ (pg/ml)
1500
1000
500
0
**
Unimmunized
None
LPS
LPS+OxPAPC

FIG. 3B



1 Immunization site
2 tumor injection site
Survivor mice
(immunized with WTL+LPS+PGPC)
Absolute number of CD8+ T cells per cm2
2.0×10^5
1.5×10^5
1.0×10^5
5.0×10^4
0.0
***
1 2
Absolute number of CD8+ CD69+ CD103+ T cells per cm2
1×10^5
8×10^4
6×10^4
4×10^4
2×10^4
0
***
1 2

FIG. 3C



1 Survivor mice
2 Unimmunized mice
Skin inguinal adipose tissue
Spleen
Absolute number of CD8+ T cells/g
Absolute number of CD8+ T cells/mouse
6×10^5
4×10^5
2×10^5
0
5×10^5
3×10^5
1×10^5
1 2
Skin inguinal adipose tissue
Spleen
Absolute number of SIINFEKL CD8+ T cells /g
Absolute number of SIINFEKL CD8+ T cells/mouse
20000
15000
10000
5000
25000
Skin inguinal adipose tissue
Spleen
Absolute number of CD8+ CD69+ CD103+ T cells/g
Absolute number of CD8+ CD69+ CD103+ T cells

FIG. 3D



TRM CD8+T cells
TCM CD8+T cells
LDH release (% of cell death)
100
50
0
B16
B16OVA
CT26
Tumor cell lines

FIG. 3E



% of survival
100
75
50
25
0
0
20
40
60
80
100
Days post tumor inoculation
No Tx
TCM (Unimmunized mice)
TCM (Survivor mice)
TRM (Survivor mice)
TCM+TRM (Survivor mice)
Immunized with WTL+LPS+PGPC

FIG. 3F



B16OVA Rechallenge
100
75
50
25
0
% of survival
0
30
60
90
120
150
Day post tumor challenge
Unimmunized
MPLA
MPLA+PGPC
MPLA+PGPC+anti IL-1β
+B16OVA WTL

FIG. 3G



100
75
50
25
0
% of survival
0
10
20
30
40
Day post tumor challenge
Unimmunized
WT
NLPR3-/-
Casp1-/-Casp11-/-
Casp11-/-
LPS+PGPC
+ B16OVA WTL

FIG. 3H



MC38OVA
Rechallenge
100
75
50
25
0
% of survival
0
50
100
150
200
Day post tumor challenge
Unimmunized
MPLA
MPLA+PGPC
MPLA+PGPC (+anti IL-1β)
MPLA+PGPC+OVA
+MC38OVA WTL

FIG. 3I



Immunization
MPLA+PGPC+WTL
MC38OVA
injection
MC38OVA
rechallenge
B16F10
Challenge
D0
D15
D50
D170
MC38OVA
Challenge
MC38OVA
Rechallenge
B16F10
Challenge
100
75
50
25
0
% of survival
0
50
100
150
200
Day post tumor challenge
Unimmunized
MPLA+PGPC+WTL

FIG. 3J




FIG. 4A




FIG. 4B




FIG. 4C




FIG. 4E




FIG. 4D




FIG. 4F



GMCSF-BMDCs
IL-1β (pg/ml)
2500
2000
1500
1000
500
0
None
MPLA
MPLA+Alum
MPLA+OxPAPC
MPLA+PGPC
Alum
OxPAPC
PGPC
GMCSF-BMDCs
TNFα (pg/ml)
10000
8000
6000
4000
2000
0
None
MPLA
MPLA+Alum
MPLA+OxPAPC
MPLA+PGPC
Alum
OxPAPC
PGPC

FIG. 5A



GMCSF-BMDCs
%LDH
80
60
40
20
0
****
None
MPLA
MPLA+Alum
MPLA+OxPAPC
MPLA+PGPC
Alum
OxPAPC
PGPC

FIG. 5B



Splenic CD11c+ DCs
IL-1β (pg/ml)
1500
1000
500
0
None
LPS
LPS+Alum
LPS+OxPAPC
LPS+PGPC
Alum
OxPAPC
PGPC
Splenic CD11c+ DCs
TNF-α (pg/ml)
2000
1500
1000
500
0
None
LPS
LPS+Alum
LPS+OxPAPC
LPS+PGPC
Alum
OxPAPC
PGPC

FIG. 5C



Splenic CD11c+ DCs
LDH release
(% of cell death)
60
40
20
0
None
LPS
LPS+Alum
LPS+OxPAPC
LPS+PGPC
Alum
OxPAPC
PGPC

FIG. 5D



CD80 (MFI)
(gated on live cells)
10000
5000
0
*
None
LPS
LPS+OxPAPC
LPS+PGPC
LPS+Alum
OxPAPC
PGPC
Alum
CD69 (MFI)
(gated on live cells)
10000
5000
0
*
*
None
LPS
LPS+OxPAPC
LPS+PGPC
LPS+Alum
OxPAPC
PGPC
Alum
MHC-I (MFI)
(gated on live cells)
80000
60000
40000
20000
0
ns
None
LPS
LPS+OxPAPC
LPS+PGPC
LPS+Alum
OxPAPC
PGPC
Alum

FIG. 5E



% of Live cells
100
80
60
40
20
0
None
LPS
LPS+OxPAPC
LPS+PGPC
LPS+Alum
OxPAPC
PGPC
Alum

FIG. 6A



None
4°C
37°C
LPS
LPS+OxPAPC
LPS+PGPC
LPS+Alum
OxPAPC
PGPC
Alum
Live/Dead
FSC-A
OVA-FITC

FIG. 6B



None
Live cells
78.1
peptide+
15.2
LPS
Live cells
73.4
peptide+
57.0
LPS+OxPAPC
Live cells
65.6
peptide+
65.4
LPS+PGPC
Live cells
75.6
peptide+
61.6
LPS+Alum
Live cells
19.1
peptide+
49.0
Live/Dead
FSC-A
H2kb bound to SIINFEKL

FIG. 6C



BMDC loaded with OVA (500µg/ml)
+OT-II (1:5)
None
LPS
LPS+
PGPC
LPS+
Alum
Live/Dead
CD4
IL-4
Gata-3
IL-4
IL-10

FIG. 7



7days post-Immunization
TEM
TCM
TCM
OVA
LPS+OVA
LPS+OxPAPC+OVA
LPS+PGPC+OVA
PGPC+OVA
CD44
CD62L

FIG. 8A



dLN CD3+ T cells
Absolute number
1×10^6
8×10^5
6×10^5
4×10^5
2×10^5
0
1 None
2 LPS
3 LPS+OxPAPC
4 LPS+PGPC
5 PGPC
Teff
TEM
1 2 3 4 5
1 2 3 4 5

FIG. 8B



Post-sorting
CD3
Live/Dead
CD8
CD4
CD8+
CD4+

FIG. 8C



dLN CD4+T cells
IFNγ (pg/ml)
3000
2000
1000
0
1 None
2 LPS
3 LPS+OxPAPC
4 OxPAPC
1000
100
10
1
0
1 2 3 4
OVA(ug/ml)
dLN CD8+T cells
IFNγ (pg/ml)
15000
10000
5000
0

FIG. 8D



PMA/IONO
E:T (1:3)
OVA
OVA+LPS
OVA+LPS+
OxPAPC
OVA+LPS+
PGPC
OVA+PGPC
CD8α
CD107a

FIG. 8E



% Tumor-Free mice
0
50
100
Unimmunized
None
LPS
LPS+OxPAPC
LPS+PGPC
+ B16OVA WTL
0/8
0/8
0/8
4/8
15/15

FIG. 9A



Unimmunized
None
LPS
LPS+PGPC
+B16 WTL
% of survival
100
75
50
25
0
0
20
40
60
80
Days post tumor challenge
% Tumor-Free mice
0
50
100
Unimmunized
None
LPS
LPS+PGPC
+ B16 F-10 WTL
0/5
0/5
0/5
3/5

FIG. 9B



% Tumor-Free mice
0
50
100
+B16OVA WTL
Unimmunized
MPLA
MPLA+PGPC+anti-IL1β
MPLA+PGPC
0/3
0/3
0/3
3/4

FIG. 9C



% Tumor-Free mice
0
50
100
+MC38OVA WTL
Unimmunized
MPLA
MPLA+PGPC
MPLA+PGPC+anti IL-1β
MPLA+PGPC+OVA
0/5
0/5
5/5
0/5
2/5

FIG. 9D



100
75
50
25
0
% of survival
0
10
20
30
40
Days post tumor challenge
Unimmunized
WTL+LPS+Alum
WTL+LPS+PGPC

FIG. 9E



100
75
50
25
0
% of survival
0
10
20
30
40
Days post tumor challenge
B16 F-10
B16-OVA
MC38-OVA
immunized with
LPS+PGPC(no WTL)

FIG. 9F



Tumor injection site
200 days post-tumor injection
Immunization injection site
200 days post-tumor injection
Gated on Live cells
Gated on CD3+CD45+
Gated on CD8+
CD45
CD3
CD4
CD8a
CD69
CD103

FIG. 10A




FIG. 10B




FIG. 10C




FIG. 11A




FIG. 11B




FIG. 11C




FIG. 11D



% of IFNγ+ CD8+T cells
80
60
40
20
0
*
**
*
None
MPLA
MPLA+PGPC
MPLA+PGPC
+WTL +OVA
100.00% IFNγ+TNFα- IL-2-
5.49% IFNγ+TNFα-IL-2+
36.50% IFNγ+TNFα+ IL-2+
21.20% IFNγ+TNFα+ IL-2-
36.80% IFNγ+TNFα- IL-2-
2.88% IFNγ+TNFα-IL-2+
74.61% IFNγ+TNFα+ IL-2+
16.50% IFNγ+TNFα+ IL-2-
6.00% IFNγ+TNFα- IL-2-
12.20% IFNγ+TNFα-IL-2+
44.30% IFNγ+TNFα+ IL-2+
11.90% IFNγ+TNFα+ IL-2-
31.60% IFNγ+TNFα- IL-2-

FIG. 11E



Immunized (or not)
WTL+LPS+PGPC
Boost
WTL+LPS+PGPC
Boost
WTL+LPS+PGPC
B16OVA
inoculation
D0
D10
D17
D24
Boost#1
Immunization
Boost#2
WT
Batf3-/-
No immunization
WT
Batf3-/-
Immunized with
WTL+LPS+PGPC
100
75
50
25
0
% of survival
0
20
40
60
Day post tumor inoculation

FIG. 12A



dLN
Tumor
Spleen
Frequency of SIINFEKL+ T cells
18
15
12
9
6
3
0
*
**
WT
Batf3-/-
Immunized with WTL+LPS+PGPC
dLN
Tumor
Spleen
Frequency of AAHAEINEA+ T cells
20
15
10
5
0.5
0.0
ns
*
*
WT
Batf3-/-
Immunized with WTL+LPS+PGPC

FIG. 12B




FIG. 13A




FIG. 13B




FIG. 13C




FIG. 13D



FLT3L-DCs
WT
NLRP3-/-
Casp1/11-/-
IL-1β (pg/ml)
1000
800
600
400
200
0
**
None
LPS
LPS+oxPAPC
LPS+PGPC
LPS+Alum
PGPC
Alum
FLT3L-DCs
LDH release (% of cell death)
80
60
40
20
0
***
None
LPS
LPS+oxPAPC
LPS+PGPC
LPS+Alum
PGPC
Alum
FLT3L-DCs
TNF-α (pg/ml)
3000
2000
1000
0
None
LPS
LPS+oxPAPC
LPS+PGPC
LPS+Alum
PGPC
Alum

FIG. 14A



FLT3L-DCs
cDC1
cDC2
IL-1β (pg/ml)
800
600
400
200
0
None
LPS
LPS+oxPAPC
LPS+PGPC
LPS+Alum
PGPC
Alum
FLT3L-DCs
cDC1
cDC2
LDH release
(% of cell death)
100
80
60
40
20
0
FLT3L-DCs
cDC1
cDC2
TNFα (pg/ml)
2500
2000
1500
1000
500
0

FIG. 14B




FIG. 15A




FIG. 15B



CD44loCD62Llo (Teff)
% of Teff CD8+ T cells
40
30
20
10
0
***
**
7d
40d
None
LPS
LPS+oxPAPC
LPS+PGPC
PGPC
+OVA
CD44hiCD62Llo (TEM)
% of TEM CD8+ T cells
8
6
4
2
0
****
7d
40d
CD44hiCD62Lhi (TCM)
% of TCM CD8+ T cells
60
40
20
0
**
**
7d
40d

FIG. 16A




FIG. 16B




FIG. 16C




FIG. 16D




FIG. 16E

FIG. 17A






FIG. 17B








FIG. 17C




FIG. 17D



Immunization
WTL+LPS+PGPC
Boost
WTL+LPS+PGPC
Boost
WTL+LPS+PGPC
B16OVA inoculation
D0
D7
D14
D21
Boost#1
Immunization
Boost#2
ZBTB46DTR
ZBTB46DTR +DT
Immunized with WTL+LPS+PGPC
100
75
50
25
0
% of survival
0
20
40
60
80
Day post tumor inoculation

FIG. 18A



Immunization
WTL+LPS+PGPC
Boost
WTL+LPS+PGPC
Boost
WTL+LPS+PGPC
B16OVA
inoculation
D0
D7
D14
D21
Boost#1
Immunization
Boost#2
ZBTB46DTR+ WT
ZBTB46DTR+ NLRP3-/-
ZBTB46DTR+ Casp1/11-/-
Immunized with
WTL+LPS+PGPC
% of survival
100
75
50
25
0
0
20
40
60
80
Day post tumor inoculation

FIG. 18B



Immunized (or not)
WTL+LPS+PGPC
Boost
WTL+LPS+PGPC
Boost
WTL+LPS+PGPC
B16OVA
inoculation
D0
D10
D17
D24
Boost#1
Immunization
Boost#2
WT
Batf3-/-
No immunization
WT
Batf3-/-
Immunized with
WTL+LPS+PGPC
100
75
50
25
0
% of survival
0
20
40
60
Day post tumor inoculation

FIG. 18C



dLN
Tumor
Spleen
Frequency of SIINFEKL+ T cells
18
15
12
9
6
3
0
*
**
WT
Batf3-/-
Immunized with WTL+LPS+PGPC
dLN
Tumor
Spleen
Frequency of AAHAEINEA+ T cells
20
15
10
5
0.5
0.0
ns
*
*
WT
Batf3-/-
Immunized with WTL+LPS+PGPC

FIG. 18D



cDC1 injection
cDC1 injection
cDC1 injection
B16OVA inoculation
D0
D7
D14
D21
100
75
50
25
0
% of survival
0
20
40
60
80
Day post tumor inoculation
No cDC1 injection
WT cDC1naive
WT cDC1active
WT cDC1hyperactive
NLRP3-/- cDC1hyperactive
CCR7-/- cDC1hyperactive
Batf3-/- recipients

FIG. 18E




FIG. 18F




FIG. 19A



SSC-A
FSC-A
DCs
77.5
B220
CD11c
8.220
84.9
CD11c
MHC-II
CD11c+MHC+
91.1
CD24
Sirpα
cDC1
22.0
cDC2
71.7
Purity post-sorting
FLT3L-DCs
cDC1
97.6
cDC2
1.12
cDC1
0.80
cDC2
98.9
Splenic-DCs
cDC1
96.8
cDC2
1.37
cDC1
0.88
cDC2
97.7
CD24
Sirpα

FIG. 19B




FIG. 19C





FIG. 20A


No DCx
WT DCNone
WT DCLPS
WT DCLPS+Alum
WT DCLPS+PGPC
NLRP3-/- DCLPS+PGPC
CCR7-/- DCLPS+PGPC
0
0.13
0.24
0.13
0.61
0.18
0.23
CD8α
SIINFEKL



Skin Inguinal dLN
% of SIINFEKL+ CD8+ T cells
0.0
0.2
0.4
0.6
0.8
**
***
**
No DCx
cDCNone
cDCLPS
cDCLPS+Alum
cDCLPS+PGPC
NLRP3-/- cDCLPS+PGPC
CCR7-/- cDCLPS+PGPC
WT

FIG. 20B



WT (No DCx)
WT cDC1hyperactive
NLRP3-/- cDC1hyperactive
NLRP3-/- recipients
100
75
50
25
0
% of survival
0
20
40
60
80
Day post tumor inoculation

FIG. 20C



6.59
8.61
TEM
TCM
Teff
81.5
OVA
3.65
9.49
8.05
OVA+LPS
78.6
4.06
13.1
2.93
OVA+LPS
+oxPAPC
51.7
32.1
13.1
3.26
OVA+LPS
+PGPC
53.2
30.3
9.81
11.4
OVA+PGPC
74.8
4.46
CD44
CD62L

FIG. 21A




FIG. 21B




FIG. 21C



PMA/IONO
E:T (1:3)
87.7
18.1
OVA
89.4
28.4
OVA+LPS
96.8
66.9
OVA+LPS+
oxPAPC
79.6
65.9
OVA+LPS+
PGPC
80.6
21.8
OVA+PGPC
CD8α
CD107α

FIG. 21D



Zbtb46DTR+ WT
Zbtb46DTR+ NLRP3-/-
Zbtb46DTR+ Casp1/11-/-
TEM
TCM
TEff
T naive
47.8
43.2
19.6
69.9
22.0
66.5
CD44
CD62L
Skin dLN
7 days post-immunization

FIG. 22A



Zbtb46DTR+ WT
Zbtb46DTR+ NLRP3-/-
Zbtb46DTR+ Casp1/11-/-
8.83
1.16
1.46
Skin dLN
7 days post-immunization
CD8
SIINFEKEL
Zbtb46DTR+ WT
Zbtb46DTR+ NLRP3-/-
Zbtb46DTR+ Casp1/11-/-
4.04
0.88
1.41
Spleen
7 days post-immunization
CD8
SIINFEKEL

FIG. 22B



Unimmunized
None
LPS
LPS+oxPAPC
LPS+PGPC
+ B16OVA WTL
Tumor Volume (mm²)
500
400
300
200
100
0
B16OVA
Rechallenge
4
14
24
34
44
150
164
174
184
194
300
Days post tumor Challenge
B16OVA
Rechallenge
100
75
50
25
0
% of survival
0
30
60
90
120
150
180
210
240
270
300
Days post tumor challenge

FIG. 23A




FIG. 23A, continued




FIG. 23B




FIG. 23C



Tumor injection site
200 days post tumor inoculation
Immunization site
200 days post tumor inoculation
CD3+ CD45
30.3
CD45+ CD3-
35.8
CD3+ CD45
0.68
CD45+ CD3-
8.81
CD3
CD45
50.1
0.80
2.72
46.4
39.8
1.11
31.6
27.5
CD4
CD8a
56.2
43.1
0.66
0.065
89.3
9.82
0.89
0
CD69
CD103

FIG. 24A




FIG. 24B




FIG. 24C



No Tx
TCM (Unimmunized mice)
TCM (Survivor mice)
TRM (Survivor mice)
TCM+TRM (Survivor mice)
immunized with WTL+LPS+PGPC
B16OVA
% of survival
100
75
50
25
0
0
20
40
60
80
100
Days post inoculation

FIG. 24D